Viagra maker Viatris misses revenue estimates on weak demand for older drugs [Reuters]
Viatris Inc. (VTRS)
Company Research
Source: Reuters
its older drugs such as cholesterol medication Lipitor and Norvasc for high blood pressure. Net sales in its branded drugs unit, which makes up two-thirds of the company's total revenues, also fell 4.5% to $2.31 billion. Viatris, formed by the merger of Mylan and Pfizer's Upjohn business, makes generic and key branded drugs such as erectile dysfunction drug Viagra, anti-anxiety medication Xanax, epilepsy treatment Lyrica and arthritis treatment Celebrex. The company last year its over-the-counter (OTC) drugs, active pharmaceutical ingredients (API) and women's health businesses. It said in February the expected timing of the deals closing will impact results for the next few quarters. On Thursday, CEO Scott Smith said the company has completed the divestiture of its women's healthcare business, while the API unit's divestiture will close imminently. Report this ad The Canonsburg, Pennsylvania-based company reported revenue of $3.65 billion for the first quarter, narrowly m
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Prevent Blindness Launches "It Started With an Eye Exam" Campaign to Encourage, Educate and Empower the Public to Make Vision and Eye Health a Part of Overall Health Care [Yahoo! Finance]Yahoo! Finance
- Viatris Inc. (NASDAQ:VTRS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast [Yahoo! Finance]Yahoo! Finance
- Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 5/9/24 - Miss
VTRS
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/26/24 - Form 10-K/A
- VTRS's page on the SEC website